- Record Financial Performance: Full-year 2025 revenue reached $3.2 billion (+467% since 2019, 34% CAGR), adjusted EBITDA totaled $205.4 million, and free cash flow was $104.5 million.
- 2026 Guidance: Revenue projected at $3.8ā4.1 billion, adjusted EBITDA at $285ā310 million, and free cash flow at $150ā180 million, driven by market expansion and Prospect synergies.
- Care Enablement Margin: The Care Enablement business operates at 20ā25% EBITDA margin, with automated workflows accelerating profitability in new markets.
- Medicaid/Exchange Challenges: Expect ~10% Medicaid disenrollment and low-tens% exchange decline in 2026, offset by improved Medicare Advantage rates and cost discipline.
- AI Infrastructure: Over 100 U.S.-based data scientists power AI tools (e.g., automated claims processing), driving operating leverage and real-time clinical insights.
Revenue Growth Drivers
The company's revenue growth is driven by sustained demand from payer and provider partners for coordinated, accountable care. Astrana Health is expanding its membership deliberately, with a focus on cultivating physician leadership and partnering with high-quality payers. The company's care enablement technology platform continues to drive operating leverage, enabling disciplined growth in new markets while expanding margins within existing businesses.
Valuation Metrics
Analyzing Astrana Health's valuation metrics, we see a P/E Ratio of 57.62, indicating a relatively high valuation compared to its earnings. The P/S Ratio is 0.41, suggesting a reasonable valuation relative to its revenue. The EV/EBITDA ratio is 9.81, which is moderate. With an ROE of 2.93% and ROIC of 2.88%, the company's profitability is modest. The Net Debt/EBITDA ratio is -3.43, indicating a healthy debt position. Analysts estimate next year's revenue growth at 11.1%, which may impact the company's valuation multiples.
Guidance and Outlook
For 2026, Astrana Health expects continued revenue growth and adjusted EBITDA expansion, driven by growth across its core and expansion markets, ramping full-risk contracts, and realization of Prospect synergies. The company guides revenue in the range of $3.8 billion to $4.1 billion, adjusted EBITDA in the range of $285 million to $310 million, and free cash flow in the range of $150 million to $180 million. The guidance reflects a prudent planning framework, considering headwinds such as Medicaid and exchange disenrollments and adverse selection.
Operational Highlights
The integration of Prospect remains on track, with the company validating the strategic rationale for the transaction. The Care Enablement business is expected to operate at a 20-25% EBITDA margin range, with a strong pipeline for care enablement clients. The company's AI tools, including automated prior authorizations and claims processing, are expected to drive further G&A improvements and scalability in expansion markets.